Brought to you by:
Educational opportunities abound at VAM 2023
Ok, so day one has lived up to the hype. From hearing about amazing research endeavors to listening to lively discussions on the latest treatment options for vascular patients, it has been very invigorating. Day two is equally packed. One…
Analyses offer a deeper dive into BEST-CLI trial data
As the vascular community continues to digest key insights from the BEST-CLI randomized controlled trial (RCT), attendees of Plenary Session 3 at the Vascular Annual Meeting (VAM) 2023, taking place 8:00–9:30a.m. Thursday morning in Potomac A/B, will be offered a…
Sex-related disparities in lower-extremity revascularization outcomes brought into focus
Women are more likely to undergo reintervention after lower extremity revascularization for peripheral arterial disease (PAD) compared to male patients with similar limb salvage and survival outcomes despite having fewer comorbidities, findings of a retrospective analysis presented during the William…
Endothelial cell granted superhero status in invited research presentation
“The endothelial cell is the superhero of the vascular system,” Kathryn L. Howe, MD, PhD, FRSCS, a vascular surgeon-scientist at the University of Toronto in Toronto, Canada, argued during an invited research presentation in Plenary Session 2 at VAM 2023.…
Significant life and limb gains for claudicants who stop smoking before lower-extremity bypass
Long-term overall survival (OS) and amputation-free survival (AFS) are outcomes that rebound in claudicants who quit smoking prior to elective surgery—and they mirror those of never smokers. But patients who don’t kick the habit have significantly worse outcomes, lighting up…
VAM is ‘in the room where it happens’
To borrow from the hit musical “Hamilton,” VAM 2023 takes place right near Washington, D.C., the seat of power, and “the room where it happens.” While the song refers to a particular room and a particular deal, “it,” can also…
Safety benefits mean TCAR may be preferable approach in radiation-induced carotid stenosis
A study set to be presented at VAM (14–17 June, National Harbor, USA) has found that the long-term outcomes of transcarotid artery revascularization (TCAR) are “not significantly affected” by prior head and neck radiation. Owing to substantially increased risks of…
Integrated vascular surgery program features may optimize trainee wellness and decrease attrition
Today’s program at the 2023 Vascular Annual Meeting (VAM) will feature the presentation of an abstract by R. Debbie Li, MD, Loyola University Medical Center, Chicago, on the divergent perceived experiences of the shared learning environment by vascular and general…
Study finds carotid stent fracture rate to be negligible but long-term research needed
Presenter Neeta Karani, MD, from Bronson Healthcare, Kalamazoo, Michigan, is set to elucidate findings that consider the incidence of carotid stent fractures and their impact on carotid stent durability during Plenary Session 2 (9:45–11 a.m.) in Potomac A/B at the…
More research needed but lithotripsy plus TCAR ‘an answer’ in certain carotid disease patients
Earlier this year, researchers debuted single-center experiences indicating that intravascular lithotripsy (IVL) may be able to expand transcarotid artery revascularization (TCAR) into patients with traditionally prohibitive calcific disease. With a multicenter case series now further suggesting IVL’s utility, but also…